Objectives: To report on linezolid exposure in a paediatric population who routinely underwent therapeutic drug monitoring (TDM) for dosage optimization and to assess the factors affecting interpatient variability.
Introduction
Infections caused by MDR Gram-positive pathogens have become a concern among hospitalized paediatric patients.
1,2 MRSA and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) are among the most frequent clinical isolates in Gram-positive infections in paediatric inpatients. 1, 3, 4 A surveillance study carried out in 149 US neonatal ICUs reported a more than 3-fold increase in late-onset MRSA-related infections between 1995 and 2004. 5 Across various studies, MRSA accounted for up to 18.1% of clinical isolates in hospitalized children. 3, 6, 7 Even higher prevalence rates have been observed for MR-CoNS, especially in neonatal units and haematology units, with percentages of 66% and 89%, respectively. 3 Linezolid is an oxazolidinone antibiotic with proven efficacy against MDR Gram-positive-related infections. The pharmacokinetic properties of this antibacterial agent are very favourable. It is available in both intravenous and oral formulations (tablets and suspension) with excellent bioavailability, it has very good tissue penetration, which is helpful for the treatment of deep-seated infections such as pneumonia and CNS infections, 8, 9 and it is eliminated mainly by a non-renal and non-hepatic clearance pathway. 10 These properties should theoretically minimize the interpatient pharmacokinetic variability. However, it has recently been shown in adults that plasma exposure to linezolid can vary severalfold, especially in the presence of certain polytherapies. 11 -13 This could be responsible for either therapeutic failure or conversely for haematological toxicity due to under-or overexposure, respectively. Accordingly, various centres rely on therapeutic drug monitoring (TDM) in order to improve the safe and effective use of this drug 11, 14, 15 and an optimal target for plasma trough concentrations has recently been proposed in adults. 15, 16 It should be noted that the benefit of TDM for linezolid might be even greater among the paediatric population. It is well known that linezolid exhibits an age-related pharmacokinetic variability among paediatric patients. The average CL in children aged 2 to 11 years is 2.3-fold higher than in adults, whereas it declines during adolescence to values similar to those observed in adults. 17, 18 Accordingly, the current paediatric dosing regimens are age differentiated, namely 10 mg/kg every 8 h in children aged 2-11 years and 600 mg every 12 h in those aged 12 -18 years old. 17, 18 Linezolid use has been licensed in paediatrics since 2002 in the USA, whereas in most European countries its use in children is still off-label. 19 In addition, linezolid prescriptions have been increasing in paediatrics both in the USA 20 and in Europe, 21 scientific evidence is sound for its use in children of any age 22 -24 and the evidence has recently been reviewed. 25 -27 This notwithstanding, clinical data on linezolid plasma exposure in paediatric hospitalized patients are very limited.
The aims of this study were to report on linezolid plasma exposure in a paediatric inpatient population who routinely underwent TDM for dosage optimization and to assess which factors might enhance interpatient variability. Additionally, a pharmacokinetic/pharmacodynamic analysis was carried out in order to investigate whether or not the currently recommended dosages might enable a high probability of target attainment (PTA) of the current pharmacological threshold for linezolid efficacy.
Methods

Study design
This was a retrospective study carried out from January 2009 to December 2013 among children who were treated with linezolid because of suspected or documented MDR Gram-positive bacterial infections at two tertiary-care hospitals in the North-East of Italy (the Clinics of Pediatrics of the Azienda Ospedaliero-Universitaria of Udine and the Institute for Maternal and Child Health, IRCSS Burlo Garofolo of Trieste), and who underwent TDM for dosage optimization of linezolid at the Institute of Clinical Pharmacology of the Azienda Ospedaliero-Universitaria of Udine. At this institution, TDM of antimicrobials is supported by clinical pharmacological advice aimed at providing clinicians with a personalized dosing regimen based on patients' pathophysiological characteristics and clinical history. 28 The study was approved by the Ethics Committee of the Azienda Ospedaliero-Universitaria of Udine. Written informed consent has always been obtained from parents, in accordance with agreed hospital policies.
Patients were divided into two age-related groups. Group 1 included children aged 2 -11 years whose initial dosing regimen was 10 mg/kg every 8 h, whereas Group 2 included children aged 12-18 years whose initial dosing regimen was 600 mg every 12 h.
TDM for the dosage optimization of linezolid was performed at the clinicians' discretion. At each TDM session a pair of venous blood samples was collected at steady state, just before the next administration to assess plasma C min , and 30 min after a 1 h intravenous infusion or 2 h after an oral administration to ascertain plasma C max . The times of the blood collections were carefully checked and samples deemed inappropriate were excluded from the analysis.
The pharmacokinetic parameters of linezolid were determined through Bayesian analysis performed using Abbotbase Pharmacokinetic System (PKS) software. 29 In instances of intravenous administration, the data were fitted to a standard one-compartment model with zero-order input (1 h drug infusion) and first-order elimination. For oral administration, the data were fitted to a standard one-compartment model with first-order absorption and first-order elimination. The estimated pharmacokinetic parameters were CL and V. The plasma AUC 24 was obtained according to the formula AUC 24 ¼daily dose/CL. Dosage adjustments of linezolid were performed in those patients presenting with potential drug under-or overexposure. Adequate exposure was defined as C min ranging between 2 and 7 mg/L and/or an estimated AUC 24 ranging between 160 and 300 mg . h/L, as previously described in adults. 11, 16 This approach was taken to enable the achievement of the currently recognized pharmacodynamic threshold of linezolid efficacy, that is an AUC 24 /MIC ratio of 80 -100, 30 ,31 against most staphylococcirelated infections, considering that the MIC 90 of linezolid for staphylococci is 2 mg/L. 32 At the same time, this choice could allow the risk of linezolid-related haematotoxicity to be contained. 16 Plasma concentrations of linezolid were analysed by means of a validated HPLC analysis method, as previously described. 11, 33 Precision and accuracy were assessed by performing replicate analyses of quality control samples against calibration standards. Intra-and inter-assay coefficients of variation were always ,10%. The low limit of detection was 0.2 mg/L.
Pharmacokinetic/pharmacodynamic evaluation by means of Monte Carlo simulation
A 10 000-subject Monte Carlo simulation was performed (with Systat version 13, Systat Software, Inc., USA) for three different dosing regimens (10 mg/kg every 8 h and 15 mg/kg every 8 h in the population aged 2 -11 years; 600 mg every 12 h in the population aged 12 -18 years) for each of the following MICs: 0.25, 0.5, 1, 2, 4, 8, 16 and 32 mg/L. The intent was to assess the PTA of an AUC 24 /MIC ratio threshold of either ≥80 or ≥100.
During each simulation a set of CLs and body weights were randomly generated, according to each mean and standard deviation of the population parameters. Two distributions of CL, one for children aged 2 -11 years old and the other for those aged 12 -18 years, were derived from previous Bayesian estimates. Likewise, two age-related distributions of body weights were calculated on the basis of the NHANES data. 34 CLs were varied according to a log-normal distribution, whereas body weights were assumed to follow a normal distribution. The CLs and body weights directly determined the AUCs of linezolid for each patient. The pharmacokinetic/pharmacodynamic susceptibility breakpoint was defined as the highest MIC at which the PTA was ≥90%.
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Data collection
For each patient the following data were retrieved: demographic characteristics, type of infection, bacterial isolate with antimicrobial susceptibility (when available), duration of treatment, daily dosage of linezolid and plasma concentrations at each instance of TDM, number of instances of TDM and concomitant drug therapies (drug, route of administration and daily dose). Haematological parameters (haemoglobin, red blood cell and platelet counts) and clinical chemistry parameters (serum creatinine) PK/PD of linezolid in children 199 JAC were retrieved both at baseline and at each subsequent instance of TDM. CL CR was calculated according to the revised Schwartz formula. 36 
Clinical outcome
Clinical outcome was classified as cured, improved, unchanged or failed according to the treatment response. A patient was classified as cured if the signs and symptoms of the infection disappeared after linezolid treatment; as improved in cases of partial clinical and/or laboratory evidence of a response to linezolid; or as unchanged or failed when no favourable clinical response was observed after linezolid treatment.
Safety outcome
Occurrences of thrombocytopenia and anaemia during linezolid treatment were defined as a reduction of more than 30%, respectively, in platelet count or haemoglobin level from baseline.
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Statistical analysis
The Kolmogorov-Smirnov test was used to assess whether data were normally or non-normally distributed. Accordingly, the mean+SD or median with IQR were used in the descriptive statistics. Categorical variables were compared by the x 2 test with Yates's correction or Fisher's exact test as necessary, and continuous variables were compared using the Student's t-test or Mann -Whitney test. A P value ,0.05 was required to achieve statistical significance.
Univariate and multivariate linear regression analyses were performed to identify independent predictors of C min . Multivariate stepwise backward analysis included all variables significant at P ≤ 0.200 in the univariate analysis. All statistical analysis were performed with Systat version 13 (Systat Software, Inc., USA).
Results
Twenty-three children were included in this retrospective analysis, 14 in Group 1 and 9 in Group 2. The patients' characteristics are reported in Table 1 . The main reasons for linezolid therapy were CNS-related infections and pneumonia in Group 1 and bone and joint infections and pneumonia in Group 2, accounting for 78.6% and 66.6% of the total, respectively. A microbiological isolate was identified in 42.9% and 66.7% of children in Group 1 and Group 2, respectively. The most frequent clinical isolate was MR-CoNS in both groups. One patient in Group 1 had two microbiological isolates.
The plasma C min and C max for linezolid are shown in Figure 1 . At first TDM, while linezolid was being administered at the recommended age-based dosing regimens, C min was below the desired range (2 -7 mg/L) in 50% and 44.4% of patients in Group 1 and Group 2, respectively, whereas it was over this threshold only for one patient in Group 2. In 70% of patients (16/23) linezolid concentrations were reassessed at least once, and among these further dosage adjustments were carried out in 32% of cases ( Figure 2 ). Overall, 51 values for C min and 36 values for C max of linezolid were available from the 23 patients, 18 of whom were treated intravenously and five orally. The median C min was above 2 mg/L in both groups (2.57 versus 2.90 mg/L in Group 1 and Group 2, respectively, P ¼0.759), but with a wide range of distribution (between 0.2 and 16.08 mg/L in Group 1 and between 0.52 and 26.04 mg/L in Group 2). Overall, the linezolid dosage was increased in 33.3% of instances of TDM in both groups, decreased in 6.6% of TDM instances in Group 1 and in 9.5% of those in Group 2, and confirmed in 60.1% and 57.2% of instances of TDM in Group 1 and Group 2, respectively.
Variables associated with the C min of linezolid are reported in Table 2 . Univariate analysis showed that some drug cotreatments were associated with the C min , either by lowering the drug exposure (phenobarbital and dexamethasone) or by augmenting it (proton pump inhibitors and amiodarone). Conversely, neither the investigated demographic parameters (age, sex, weight and body surface area) nor renal function estimates correlated with the C min of linezolid. Stepwise multivariate linear regression analysis confirmed that a concomitant use of proton pump inhibitors or of amiodarone was associated with an increased C min , whereas a concomitant use of phenobarbital was correlated with a decreased C min . Interestingly, the adjusted R 2 of 0.692 proved that more than two-thirds of the variability in C min of linezolid among our population was related to the co-administration of these drugs. Figure 3 shows the pharmacokinetic/pharmacodynamic PTA of linezolid by MIC when considering the three different dosing regimens in the two age-related paediatric populations. Mean+SD Bayesian estimates for CL were 0.152+0.074 versus 0.067+0.04 L/h/kg in Group 1 and Group 2, respectively (P , 0.001). Mean+SD body weights based on NHANES data were 23.28+12.74 kg versus 61.20+15.56 kg in Group 1 and Group 2, respectively (P , 0.001). On the basis of simulation results, a PTA of ≥90% for both thresholds of AUC/MIC ratio was achieved with all regimens in both patient populations for an MIC of ≤1 mg/L. However, when considering an MIC of 2 mg/L, only the dosage of 15 mg every 8 h allowed the achievement of a nearly optimal PTA in Group 1, similar to what was observed in Group 2 with a dosage of 600 mg every 12 h (88.6% versus 89.5% for an AUC/MIC ratio ≥80; 81.0% versus 80.6% for an AUC/MIC ratio ≥100 in Group 1 and Group 2, respectively). At an MIC of 4 mg/L both these dosing regimens resulted in a suboptimal PTA (55.0% versus 54.9% for an AUC/MIC ratio of ≥80; 40.6% versus 40.9% for an AUC/MIC ratio of ≥100 in Group 1 and Group 2, respectively). Conversely, the standard regimen of 10 mg every 8 h resulted in a suboptimal PTA in Group 1 only for an MIC of 2 mg/L (71.8% and 58.7% for an AUC/MIC ratio of ≥80 and ≥100, respectively), with unacceptably low PTAs at an MIC of 4 mg/L (30.1% and 19.2% for an AUC/MIC ratio of ≥80 and ≥100, respectively).
In 10 out of 23 patients a true pharmacokinetic/pharmacodynamic analysis was performed thanks to the identification of bacterial clinical isolates (Table 3) . Interestingly, after optimization of linezolid treatment by TDM all of these patients had an AUC 24 /MIC ratio of ≥80, and all but one had an AUC 24 /MIC ratio of ≥100, with clinical cure in all but one case. Figure 4 depicts nadir versus baseline plots of haemoglobin ratio (a) and of platelet count ratio (b) during linezolid treatment. No patient experienced anaemia during linezolid treatment. Conversely, 8 out of 23 patients (34.8%) experienced a platelet reduction greater than 30%. The median C min in these patients was 7.17 mg/L (range 2.55 -26.04 mg/L). It should be noted that four of these eight patients were also receiving antineoplastic chemotherapy because of haematological malignancies and experienced a highly significant reduction in platelet ratio (ranging from 0.50 to 0.12). A discontinuation of linezolid therapy was not deemed necessary in any of these cases, but a dosage reduction Cojutti et al.
was provided in three cases. Among the other four patients, the lowest absolute platelet count was 160×10 3 cells/mm 3 .
Discussion
Our study aimed to address the issue of interpatient variability of linezolid exposure in a paediatric inpatient population. Interestingly, the findings suggest that a suboptimal plasma C min occurred at the first instance of TDM in approximately half of all cases in both age-related groups while patients were receiving the recommended age-differentiated standard dosing regimen of linezolid. Accordingly, dosage increases were applied in almost one-third of cases among those patients who underwent further instances of TDM. It is noteworthy that the high frequency of a low drug exposure with standard dosages of linezolid could help to explain the increasing prevalence of coagulase-negative staphylococci with resistance to linezolid in the paediatric setting. 38 High interindividual variability with a particular risk of drug underexposure was recently reported among adult patients who had the linezolid C min assessed during treatment with the standard dosing regimen of 600 mg every 12 h. In two retrospective studies carried out among patients with different types of infections, a linezolid C min of ,2 mg/L was documented in 29% 11 and 29.5% 39 of subjects, respectively. Similarly, in a prospective To the best of our knowledge, the only two studies reporting data on the plasma C min values of linezolid in children support the idea that suboptimal exposure after standard dosages may be worrisome even in the paediatric population. The first study 41 included four patients aged ,3 years who were treated with linezolid at 10 or 15 mg/kg every 8 h because of MRSA mediastinitis following cardiac surgery. A linezolid C min of ,2 mg/L was observed in two out of four instances of TDM performed while patients were being treated with the 10 mg/kg every 8 h dosing regimen, and one out of the two instances of TDM performed while patients were being treated with the dosing regimen of 15 mg/kg every 8 h. Likewise, the second study, 42 which was carried out among 10 patients with cystic fibrosis aged 4 -20 years who were treated with the dosing regimen of 10 mg/kg every 8 h, showed the occurrence of a linezolid C min of ,2 mg/L in three younger patients aged between 4 and 6 years.
An investigation of potential factors affecting the C min of linezolid in our patient population showed that more than two-thirds of interpatient variability could be explained by the co-administration of some drugs, namely phenobarbital, proton pump inhibitors and amiodarone, as documented by the multivariate analysis. Whereas phenobarbital was associated with decreased plasma exposure, the latter two drugs were conversely associated with an augmented C min of linezolid.
Of note, relevant drug -drug pharmacokinetic interactions of linezolid with the aforementioned drugs or even with others have recently been reported in adults. 11, 13, 43, 44 The putative mechanism underlying such interactions could rely on a modulation of P-glycoprotein activity, linezolid being a potential substrate for this extrusive pump. 43 Proton pump inhibitors, amiodarone Cojutti et al.
and calcium channel blockers have been shown to be potent P-glycoprotein inhibitors, 45, 46 whereas phenobarbital and rifampicin behave as P-glycoprotein inducers. 47 Indeed, although in our study rifampicin was one of the tested co-treatments, it was not significantly associated with the C min of linezolid in the univariate analysis, but this is probably the consequence of the paucity of TDM samples coming from patients co-treated with this drug.
As far as the role of other factors potentially affecting the interpatient variability in linezolid C min is concerned, none of the other tested variables showed any significant correlation with the C min of linezolid in our cohort. Indeed, it should be recognized that, for CL CR estimates, the lack of statistical significance in the univariate analysis was borderline. Although this may be in agreement with the fact that CL R accounts for only 30% of the total linezolid CL, 48 it is worth mentioning that, in a recent retrospective study of 78 adult patients, glomerular filtration estimates of .80 mL/min were found to be an independent predictor of a linezolid C min of ,2 mg/L, with an odds ratio of 10. 39 Additionally, it should also be considered that some authors have reported higher concentrations of linezolid in patients with renal failure with increased drug-related toxicity rates. 49 -51 Accordingly, no definitive conclusion on this aspect can be drawn.
The pharmacokinetic/pharmacodynamic analysis based on the Monte Carlo simulation showed that the two currently recommended age-differentiated dosing regimens of linezolid in children (10 mg/kg every 8 h in those aged 2 -11 years and 600 mg every 12 h in those aged 12 -18 years) may allow an optimal PTA to be achieved in the presence of bacterial pathogens with an MIC of linezolid of ≤1 mg/L. Conversely, in the presence of staphylococci with higher MIC values approaching the clinical breakpoint, namely 2 or 4 mg/L, higher doses would be beneficial to optimize drug exposure, especially among children aged 2 -11 years, who are known to exhibit higher CL rates.
These results are in agreement with the findings of Santos et al., 42 who showed that an AUC/MIC ratio of .80 was never achieved among 10 children treated with the 10 mg/kg every 8 h dosing regimen of linezolid because of MRSA-associated pulmonary exacerbations of cystic fibrosis, most of which were caused by strains with an MIC of 2 mg/L. Consistently, the authors concluded that higher linezolid doses would be needed to attain this goal, especially in patients aged ,10 years.
Interestingly, our pharmacokinetic/pharmacodynamic analysis showed that increasing the dosing regimen in children aged 2 -11 years at 15 mg/kg every 8 h would also allow an almost optimal PTA for pathogens with an MIC of 2 mg/L, with percentages close to 90%, similar to what is observed in children Considering that 2 mg/L is the MIC 90 of linezolid for both MRSA and MR-CoNS, 32 this means that the administration of linezolid at a dosage of 15 mg/kg every 8 h to children aged 2-11 years and a dosage of 600 mg every 12 h to those aged 12 -18 years would allow an optimal PTA in most paediatric patients.
However, since the clinical breakpoint of linezolid for staphylococci is set at 4 mg/L, it should not be overlooked that these dosing regimens could be suboptimal in the presence of pathogens with a borderline susceptibility to linezolid. The optimization of linezolid exposure by means of TDM could be of paramount importance in these cases. Likewise, the role of TDM might be relevant also for those paediatric patients in whom it is expected that linezolid exposure might be altered, such as in those co-treated with P-glycoprotein modulators 44, 52 and/or in those who are critically ill. 53 It should be noted that, in the 10 patients in whom a true pharmacokinetic/pharmacodynamic analysis was feasible in our study, we provided evidence that an optimization of linezolid exposure by means of real-time TDM allowed the attainment of an optimal AUC/MIC ratio with favourable outcomes in all but one of the assessable patients.
In this regard, several authors have advocated TDM as a useful tool to improve the safe and effective use of linezolid. 11,14,16,39,54 -56 Indeed, the safety profile of linezolid may be of concern for clinicians, especially in long-term use, with thrombocytopenia being the most common dose-dependent haematological adverse effect. 57 -59 The fact that most patients in our study did not experience linezolid-related thrombocytopenia, and that no patient needed a discontinuation of linezolid therapy, supports the helpful role of TDM also in avoiding drug overexposure by maintenance of C min in the range between 2 and 7 mg/L. 15, 16, 55 We recognize that our study has some limitations. The limited sample size and the retrospective nature of our investigation are probably the most relevant. Sparse clinical data could have hampered CL estimates as not all ages were represented in both groups. Additionally, the heterogeneity of the patient case-mix, including both patients with chronic albeit stable infections and those with acute infections in the presence of underlying haematological diseases, could have hidden the role of some other factors.
In conclusion, our study showed that the currently recommended age-differentiated standard dosing regimens of linezolid resulted in a suboptimal plasma C min of linezolid in approximately half of all cases among hospitalized children. Higher than standard dosages may be needed, especially in children aged 2 -11 years in the presence of pathogens with an MIC .1 mg/L. However, the usage of TDM should be encouraged in order to optimize linezolid exposure even in the paediatric setting, particularly in the presence of documented or suspected infections caused by pathogens with borderline susceptibility to linezolid and/or with patients co-treated with drugs such as proton pump inhibitors, phenobarbital and amiodarone, that may significantly alter plasma linezolid exposure. Larger and prospective clinical studies are clearly warranted to provide definitive evidence.
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